0001179110-20-010900.txt : 20201106 0001179110-20-010900.hdr.sgml : 20201106 20201106182801 ACCESSION NUMBER: 0001179110-20-010900 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20201104 FILED AS OF DATE: 20201106 DATE AS OF CHANGE: 20201106 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Chapman Steven Leonard CENTRAL INDEX KEY: 0001711968 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37478 FILM NUMBER: 201295574 MAIL ADDRESS: STREET 1: 201 INDUSTRIAL ROAD, SUITE 410 CITY: SAN CARLOS STATE: CA ZIP: 94070 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Natera, Inc. CENTRAL INDEX KEY: 0001604821 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071] IRS NUMBER: 010894487 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 201 INDUSTRIAL ROAD STREET 2: SUITE 410 CITY: SAN CARLOS STATE: CA ZIP: 94070 BUSINESS PHONE: 650-249-9090 MAIL ADDRESS: STREET 1: 201 INDUSTRIAL ROAD STREET 2: SUITE 410 CITY: SAN CARLOS STATE: CA ZIP: 94070 4 1 edgar.xml FORM 4 - X0306 4 2020-11-04 0 0001604821 Natera, Inc. NTRA 0001711968 Chapman Steven Leonard C/O NATERA, INC., 201 INDUSTRIAL ROAD SUITE 410 SAN CARLOS CA 94070 1 1 0 0 Chief Executive Officer Common Stock 2020-11-04 4 M 0 2188 9.59 A 39088 D Common Stock 2020-11-04 4 M 0 4468 10.41 A 43556 D Common Stock 2020-11-04 4 M 0 2083 10.73 A 45639 D Common Stock 2020-11-04 4 M 0 6105 9.29 A 51744 D Common Stock 2020-11-04 4 M 0 3125 13.01 A 54869 D Common Stock 2020-11-04 4 M 0 13541 20.27 A 68410 D Common Stock 2020-11-04 4 S 0 36115 75 D 32295 D Common Stock 2020-11-04 4 M 0 20312 13.01 A 52607 D Common Stock 2020-11-04 4 S 0 25236 75 D 27371 D Stock Option (right to buy) 9.59 2020-11-04 4 M 0 2188 0 D 2026-04-07 Common Stock 2188 0 D Stock Option (right to buy) 10.41 2020-11-04 4 M 0 4468 0 D 2027-06-08 Common Stock 4468 23461 D Stock Option (right to buy) 10.73 2020-11-04 4 M 0 2083 0 D 2027-07-13 Common Stock 2083 10417 D Stock Option (right to buy) 9.29 2020-11-04 4 M 0 6105 0 D 2028-03-08 Common Stock 6105 67156 D Stock Option (right to buy) 13.01 2020-11-04 4 M 0 3125 0 D 2029-01-10 Common Stock 3125 66666 D Stock Option (right to buy) 20.27 2020-11-04 4 M 0 13541 0 D 2029-04-11 Common Stock 13541 71875 D Stock Option (right to buy) 13.01 2020-11-04 4 M 0 20312 0 D 2020-01-10 Common Stock 20312 81250 D The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 30, 2019 as amended on February 28, 2020. The Reporting Person is subject to a Lock-up Letter Agreement that expires on November 10, 2020. The sale of shares is a permissible exemption under the terms of the Lock-Up Letter Agreement. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 15, 2020. The sale of shares is a permissible exemption under the terms of the Lock-Up Letter Agreement. These reported shares are subject to restrictions in the Lock-Up Letter Agreement. The option shares vest over four years. 25% of the option shares vested and became exercisable on April 1, 2017 and the remaining shares vest in 36 equal monthly installments thereafter. The option shares vest over four years. 25% of the option shares vested and became exercisable on March 21, 2018 and the remaining shares vest in 36 equal monthly installments thereafter. The option shares vest over four years. 25% of the option shares vested and became exercisable on March 12, 2018 and the remaining shares vest in 36 equal monthly installments thereafter. The option shares vest over four years. 25% of the option shares vested and became exercisable on March 9, 2019 and the remaining shares vest in 36 equal monthly installments thereafter. The option shares vest over four years. 25% of the option shares vested and became exercisable on January 2, 2020 and the remaining shares vest in 36 equal monthly installments thereafter. The option shares vest over four years. 25% of the option shares vested and became exercisable on March 22, 2020 and the remaining shares vest in 36 equal monthly installments thereafter. This option becomes exercisable, if at all, upon the Reporting Person achieving certain milestones relating to a combination of the passage of time and the Reporting Person achieving certain milestones relating to the Issuer's stock price, based on the average closing price per share of the Issuer's common stock for a calendar month, calculated as of the last day of such calendar month. The first milestone is the Issuer's stock price equaling or exceeding the quotient of (i) $2,000,000,000 and (ii) the Issuer's outstanding shares as most recently reported on the Issuer's Form 10-Q or Form 10-K (the "Capitalization"). The second milestone is the Issuer's stock price equaling or exceeding the quotient of (i) $3,000,000,000 and (ii) the Capitalization (the "Performance Vesting Conditions"). As of June 23, 2020, the Company's Board of Director determined the performance criteria had been met with respect to 18,750 additional shares. /s/ Tami Chen, attorney-in-fact 2020-11-06